Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease

enthalten in: Movement disorders | 2017

von Visanji, N. | Bhudhikanok, G. | Mestre, T. | +19

Heart rate variability in leucine‐rich repeat kinase 2‐associated Parkinson's disease

enthalten in: Movement disorders | 2017

von Visanji, N. | Bhudhikanok, G. | Mestre, T. | +19

Reply to: Gray et al

enthalten in: Movement disorders | 2014

von Visanji, N. | Marras, C. | Liu, L. | +2

Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa‐induced dyskinesia

enthalten in: Movement disorders | 2014

von Visanji, N.

Alimentary, my dear Watson? The challenges of enteric α‐synuclein as a Parkinson's disease biomarker

enthalten in: Movement disorders | 2014

von Visanji, N. | Marras, C. | Hazrati, L. | +2

Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease

enthalten in: Movement disorders | 2012

von Huot, P. | Johnston, T. | Visanji, N. | +5

The nociceptin-orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease Potential conflict of interest: None reported.

enthalten in: Movement disorders | 2008

von Visanji, N. | de Bie, R. | Johnston, T. | +3

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

enthalten in: Movement disorders | 2006

von Gomez-Ramirez, J. | Johnston, T. | Visanji, N. | +2

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease

enthalten in: Movement disorders | 2006

von Visanji, N. | Gomez-Ramirez, J. | Johnston, T. | +4